Chinese online pharmacy Yaoshibang raises ~$65.7M Series C led by Shunwei Capital and DCM Ventures, bringing total raised to ~$93.8M
Yimian Wu / China Money Network :
Context & Ripple Effects
Yaoshibang's ~$65.7M Series C, led by Shunwei Capital and DCM Ventures, lifts its total funding to ~$93.8M and puts fresh institutional weight behind online pharmaceutical retail in China at mid-2018 valuations of discipline rather than blitzscale.
The round sits inside a broader run of Chinese consumer-health financing in this coverage: medical-expense crowdfunding platforms Shuidi and Shuidichou raised successive Tencent-led rounds, and two years later rival Miaoshou Doctor pulled in ~$84M for a telehealth-plus-online-pharmacy marketplace — evidence the category Yaoshibang backed into kept drawing larger checks.
First-order effects
- Shunwei Capital and DCM Ventures now hold lead positions in a Chinese online pharmacy with under $100M raised, betting that prescription and OTC drug e-commerce can scale on logistics and licensing moats rather than subsidy burn.
- Yaoshibang gains the balance sheet to expand fulfillment and supplier relationships while competitors in the same basket — notably Miaoshou Doctor — are still earlier in their funding arcs.
Second-order effects
- Miaoshou Doctor's response path is visible in the coverage: bundling telehealth consultations with a pharmaceuticals marketplace to differentiate from pure drug retail, a strategy its own ~$84M Series D later funded.
- Crowdfunding platforms like Shuidi sit adjacent to the same patient wallet, so capital crowding into online pharmacies pressures the whole consumer-health stack to integrate payment, consultation, and drug delivery rather than compete as isolated services.
Third-order effects
- If the pattern holds, Chinese healthcare distribution consolidates around vertically integrated online platforms — pharmacy, telehealth, and payment in one flow — with venture rounds escalating from tens of millions to hundreds as the winners emerge; whether regulators treat drug e-commerce like retail or like clinical care is the open variable the corpus does not resolve.
The trend: China's consumer-health spending is migrating online, with venture capital scaling up rounds across pharmacies, telehealth, and crowdfunding as each layer seeks to absorb the others.